ENLIVEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 1.80M shares.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.44M shares.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 31.45K shares, a 39.90% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 158.68K shares, a 40.33% decline from fiscal 2020.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 265.94K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 1.80M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | |
| 2026-03-31 | 1.44M shares 10-Q · filed 2026-05-07 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 158.68K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 31.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 328.02K shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 58.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 348.90K shares derived: sum of 4 quarters · filed 2021-08-06 |
| 2021-03-31 | 68.28K shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 169.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | 265.94K shares 10-K · filed 2021-03-05 |
| 2020-09-30 | 52.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |